Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the symbol lookup tool.
Alphabetize the sort order of my symbols
F4Q08 Earnings Call
September 5, 2008 10:00 am ET
Ted Ayvas – Director IR & Corporate Communications
Douglas Roth - CFO
Leonard Schwartz - Chairman, CEO and President
Hank Gracin – Securities Counsel of Lehman & Ellen
Scott Nussbaum – Broadlawn Capital
Daniel Rizzo – Sidoti & Company
David Jordan – Axiom Capital Management
Christopher Schultz – York Asset Management
Steve Bush – South Paw Investment.
Gene Fox – Cardinal Capital Management
Roger Feldman – West Creek Capital
Lenny Dunn – Freedom Investors
Welcome to the Aceto Corporation fiscal 2008 fourth quarter earnings results conference call. (Operator Instructions)
Previous Statements by ACET
» Aceto Corporation Q1 2010 Earnings Call Transcript
» Aceto Corp., F2Q09 (Qtr End 12/31/08) Earnings Call Transcript
» Aceto Corporation F1Q09 (Qtr End 09/30/08) Earnings Call Transcript
The forward-looking statements contained in this conference call may include but are not limited to statements regarding the Company’s strategic initiatives, including selling finished dosage form generic drugs, providing vaccines for companion animals, entering the Japanese pharmaceutical market, the globalization of our nutraceutical business, committing the necessary resources to grow the Company’s business in Vietnam, capitalizing on the sourcing opportunities in highly volatile markets, China and India, and prospects for long-term growth.
All forward-looking statements are made as of the date of this conference call and Aceto assumes no obligation to update them, other than as required by law. Results that could actual results to differ materially from those set forth or implied by any forward-looking statements can be found in Aceto’s filings with the Securities and Exchange Commission, which are available at www.sec.gov.
Now I would like to turn today’s conference over to Mr. Ted Ayvas, Director of Investor Relations and Corporate Communication.
Good morning and welcome to Aceto Corporation fiscal 2008 fourth quarter conference call and audio webcast. With me today is Leonard Schwartz, our Chairman, President, and CEO; Douglas Roth, our Chief Financial Officer; and Hand Gracin of Lehman & Ellen, our outside Securities Counsel.
During this call, Doug will give an overview of the Company’s results for the fiscal fourth quarter and year end June 30, 2008, and Len will discuss the performance of our business segment and provide an update on the strategic initiatives for growth. Following that we will open the call up for questions.
Now, I’d like to turn the call over to Doug Roth.
We are very pleased with the operating results that we have reported this quarter. Both our quarterly and fiscal year results represent record levels of sales, gross profit, net income, and earnings per share and in the case of the fiscal year, these results represent the second consecutive year of record sales and gross profits.
Now let’s take a look at the numbers, looking at the fourth quarter first. Sales increased 20% to $105 million compared to $87 million in the comparable 2007 quarter. Gross profit increased 47% to $24 million from $16.5 million last year. Operating income also increased 104% to $12 million from $5.8 million in the fiscal fourth quarter of 2007. Net income increased 90% to $8 million, the highest quarterly net income ever recorded at Aceto compared to $4.2 million for the 2007 comparable quarter. Earnings per diluted share were $0.32 in the fiscal fourth quarter, surpassing the $0.17 that we recorded last year and also this is compared to the guides at $0.21 per diluted share that we provided with our third quarter results.
Now looking at the full-year results for fiscal 2008, net sales were recorded at $360 million, a 14.7% increase over last year’s results of $313.5 million. Gross profit also increased 23.5% to $67 million compared to $55 million in 2007 comparable period and operating income of 42% to $21.4 million in 2008 compared to $15.1 million in fiscal 2007. The resulting net income was $13.5 million or $0.54 per diluted share compared to $10.2 million or $0.41 for the full-year fiscal 2007.
Now I’d like to turn the call over to Len.
Obviously, we are very, very pleased with the results. We are really, really pleased. In the fourth quarter, all our business segments performed well, particularly our Health Sciences and Crop Protection segment as evidenced by the across-the-board increase in sales. Sales in our Health Sciences segment grew 35% largely the result of increased sales in both our foreign and domestic operations. We did [inaudible]. This segment was especially profitable for Aceto generating 71% of our fourth quarter gross profit.
This increase in sales can be attributed to the increased line of business for existing products, some of which were more profitable than others. Sales in our Crop Protection segment increased almost 20% from the 2007 comparable quarter, largely the result of increased sales of an herbicide using peanuts, as well as an increase in sales in our sprout inhibitor products, which are used on potato crops. This is a post-emerging prior.
Chemicals & Colorants sales showed modest growth of about 1%. I’d now like to provide you with an update on our current strategic initiatives. Our initiatives to provide vaccines to companion animals continues to move forward. The animal challenge retesting has been completed, and the results which confirm the results with the first set of testing that the vaccine if efficacious. These results have been fully submitted to the USDA. Some of you may recall that we had to redo the testing because the FDA made a mistake in the protocol, although the first set of results showed as efficacious, means it works.